Pharvaris NV (FRA:9EN) Dividend Payout Ratio: 0.00 (As of Mar. 2026)


FRA:9EN Pharvaris NV FRA:9EN
28 GF Score
Price €30.70
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Dividend Payout Ratio?

Pharvaris NV FRA:9EN -1.76% 28 Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus rates FRA:9EN with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 133 Biotechnology companies, Pharvaris NV ranks worse than 751878.95% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Pharvaris NV's Dividend Payout Ratio for the months ended in Mar. 2026 was 0.00.

The historical rank and industry rank for Pharvaris NV's Dividend Payout Ratio or its related term are showing as below:


FRA:9EN's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-07-11), the Dividend Yield % of Pharvaris NV is 0.00%.

Pharvaris NV's Dividends per Share for the months ended in Mar. 2026 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Pharvaris NV (FRA:9EN) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Pharvaris NV Dividend Payout Ratio Related Terms


Pharvaris NV Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Pharvaris NV's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharvaris NV Dividend Payout Ratio Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharvaris NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:9EN vs BHVN, NRIX, VCEL: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Pharvaris NV's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharvaris NV Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Dividend Payout Ratio falls into.


FRA:9EN
28GF Score
Pharvaris NV FRA:9EN
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Pharvaris NV's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ -2.841
=N/A

Pharvaris NV's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.599
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Pharvaris NV (FRA:9EN) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #999999 out of 133 companies in the Biotechnology industry.
Is Pharvaris NV's Dividend Payout Ratio too high?
Pharvaris NV's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Pharvaris NV ranks #999999 out of 133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharvaris NV has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Dividend Payout Ratio compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #999999 out of 133 companies for Dividend Payout Ratio. This places Pharvaris NV in the lower half of its industry. The industry median Dividend Payout Ratio is 0.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.44, based on 133 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Pharvaris NV and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (FRA:9EN) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Pharvaris NV's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Pharvaris NV (FRA:9EN), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges PHVS:USA
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score

Get the complete analysis for FRA:9EN

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.70
Price